Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 8290546.
- Also identified by PMC identifier 42965.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A synthetic peptide corresponding to an immunodominant epitope of lymphocytic choriomeningitis virus glycoprotein (LCMV GP) was used to prime or to tolerize CD8+ T cells in vivo, dependent on mode of immunization. Peptide-specific tolerance was then examined in transgenic mice expressing LCMV GP in the beta islet cells of the pancreas; these mice develop CD8+ T-cell-mediated diabetes within 8-14 days after LCMV infection. Specific peptide-induced tolerance prevented autoimmune destruction of beta islet cells and diabetes in this transgenic mouse model.
Medical subject headings
- Autoimmune Diseases
- Diabetes Mellitus, Experimental
- Oligopeptides
- T-Lymphocytes, Cytotoxic